NBIX vs VERO · P/E 45, rev $1.77B vs rev $64.8M
Neurocrine Biosciences Inc (NBIX) versus Venus Concept Inc (VERO) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Venus Concept Inc (VERO) is a medical devices company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported VERO revenue for 2024-12-31 was $64.8M. Net income was -$47.0M. Revenue was down 15.1% from 2023-12-31 to 2024-12-31. VERO currently screens at market cap $578.2K.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. VERO currently screens at market cap $578.2K.
Not investment advice. Open the NBIX and VERO stock pages for the full models.
Not investment advice.